文献速递类风湿关节炎

停用TNF抑制剂对类风湿关节炎患者疾病负担的影响

Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-01-01

POET试验纳入817例处于缓解或稳定低疾病活动度的RA患者,按2:1随机分为停用或继续TNFi组。停用组3个月时多项患者报告结局显著变差,效应量以健康效用和疼痛最强;12个月内47.5%重新启用TNFi,6个月内重启者12个月时结局与未重启者无显著差异。

要点

  • 停用TNFi在3个月时对多项PROs产生显著负面影响,疼痛和健康效用效应量最大。
  • 停用组12个月内47.5%重新启用TNFi,6个月内重启者12个月时PROs与未重启者无显著差异。
  • 12个月时残疾评分仍显著差异,但长期负面后果似乎有限。

核心结论

  • 停用TNFi对广泛PROs有显著短期负面影响,但长期负面后果似乎有限。

研究设计与样本

  • 实用性12个月POET试验,817例病程明确的RA患者按2:1随机分为停用或继续TNFi。

主要发现

  • 停用组3个月时平均PRO评分显著更差,更多患者达到MCID。
  • 效应量最强为健康效用(ES -0.24)和疼痛(ES -0.30)。
  • 12个月时相对风险从精神健康状态的1.16到疲劳的1.58。
  • 6个月内重启TNFi者12个月时PROs与未重启者无显著差异。

关键数值与推荐

  • 纳入患者需≥6个月缓解或稳定低疾病活动度。
  • 停用组12个月内重启TNFi比例为252/531(47.5%)。

临床怎么用

  • 对已稳定RA患者停用TNFi需预期短期PROs恶化,并在6个月内重启可恢复结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the impact of stopping tumor necrosis factor inhibitor (TNFi) treatment on patient-reported outcomes (PROs) of physical and mental health status, health utility, pain, disability, and fatigue in patients with established rheumatoid arthritis (RA). METHODS: In the pragmatic, 12-month POET trial, 817 RA patients with ≥6 months of remission or stable low disease activity were randomized 2:1 to stopping or continuing TNFi. In case of flare, TNFi was restarted at the discretion of the rheumatologist. PROs were assessed every 3 months. RESULTS: TNFi was restarted within 12 months in 252 of 531 patients (47.5%) in the stop group. At 3 months, mean PRO scores were significantly worse in the stop group, and a larger proportion of patients experienced a minimum clinically important difference (MCID) on all PROs. Effect sizes (ES) were strongest for health utility (ES -0.24) and pain (ES -0.30). Mean scores improved again after this point, but disability scores remained significantly different at 12 months. After 12 months, the relative risk of experiencing an MCID ranged from 1.16 for mental health status to 1.58 for fatigue. Mean PRO scores for patients restarting TNFi within 6 months were no longer significantly different from those that did not restart TNFi at 12 months. CONCLUSION: Stopping TNFi had a significant negative short-term impact on a broad range of PROs. Long-term negative consequences appeared to be limited, and outcomes in patients needing to restart TNFi within the first 6 months tended to be restored at 12 months.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Ghiti Moghadam M, Ten Klooster PM, Vonkeman HE, et al. Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease. Arthritis Care Res (Hoboken). 2018. PMID: 28692770. doi:10.1002/acr.23315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。